Evidence map›Paper›PMID 38114800›Full record

ArticleApoptosis : an international journal on programmed cell death2024

A novel safer CD19CAR with shRNA interference of IFN-γ can reduce multiple cytokine levels without significantly compromising its killing efficacy.

Ping Zhang, Peiting Ying, Hongzhe Li, Ning Zhao, Rongrong Liu, Sisi Li, Weiqun Xu, Yang Tang, Yongmin Tang

Abstract read
PubMed Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ping Zhang *Department/Center of Hematology-oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, PR China.
Peiting Ying *Department/Center of Hematology-oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, PR China.
Hongzhe LiDepartment/Center of Hematology-oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, PR China.
Ning ZhaoDepartment/Center of Hematology-oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, PR China.
Rongrong LiuDepartment/Center of Hematology-oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, PR China.
Sisi LiDepartment of Clinical Medicine, School of Medicine, Hangzhou City University, No. 50, Huzhou Street, Gongshu District, Hangzhou, Zhejiang Province, 310015, PR China.
Weiqun XuDepartment/Center of Hematology-oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, PR China.
Yang TangDepartment of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevetion and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province, 310009, PR China. tyx90@zju.edu.cn.
Yongmin TangDepartment/Center of Hematology-oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, PR China. y_m_tang@zju.edu.cn.
Children's Hospital of Zhejiang University · CNHangzhou City UniversityNational Health and Family Planning Commission · CNZhejiang University · CN

Funding

Key Project from Science and Technology Department of Zhejiang Province No. 2019C03032National Natural Science Foundation of China No. 81770202 and 81470304Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province No. JBZX-201904Scientific Research Foundation of Zhejiang University City College J-202103Zhejiang Medical and Health Science and Technology Plan Project No. 2022KY868Zhejiang Provincial Health Commission of China No. 2022485642
6 · The paper itself

Abstract

Cytokine release syndrome (CRS) is a great challenge for the application of anti-CD19 CAR-T cell therapy. The aim of this study was to investigate the effect of knocking down interferon gamma (IFN-γ) by shRNA as a potential strategy to reduce the cytokine storms. A newly designed short hairpin interference RNA of IFN-γ (shIFN-γ) in CD19CAR gene was constructed. Several cellular model systems of approach using Nalm-6 cell lines including Nalm-6

Indexed as

CytokinesInterferon-gammaAnimalsApoptosisCytokine Release SyndromeEndothelial CellsMiceCytokinesInterferon-gammaAcute lymphoblastic LeukemiaChimeric antigen receptorCytokine release syndromeInterferon-γRNA interference

Identifiers

PMID38114800
OpenAlexW4389944760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.